6-fluro-5-[4-(5-fluoro-2,3-dihydrobenzofuran-7-yl)-2-hydroxy-4-methyl-2-trifluoromethyl-pentylamino]-2-methylquinoline | 887375-34-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 6-fluro-5-[4-(5-fluoro-2,3-dihydrobenzofuran-7-yl)-2-hydroxy-4-methyl-2-trifluoromethyl-pentylamino]-2-methylquinoline
• 英文别名: 6-fluoro-5-[4-(5-fluoro-2,3-dihydrobenzofuran-7-yl)-2-hydroxy-4-methyl-2-(trifluoromethyl)-pentylamino]-2-methylquinoline；6-Fluoro-5-[4-(5-fluoro-2,3-dihydrobenzofuran-7-yl)-2-hydroxy-4-methyl-2-trifluoromethyl-pentylamino]-2-methylquinoline；1,1,1-trifluoro-4-(5-fluoro-2,3-dihydro-1-benzofuran-7-yl)-2-[[(6-fluoro-2-methylquinolin-5-yl)amino]methyl]-4-methylpentan-2-ol
• CAS: 887375-34-0
• 化学式: C₂₅H₂₅F₅N₂O₂
• 分子量: 480.478
• InChiKey: GUOCMHPAIQLFTR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.3
• 重原子数：
  34
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  54.4
• 氢给体数：
  2
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  、 4-(5-fluoro-2,3-dihydrobenzofuran-7-yl)-2-hydroxy-4-methyl-2-trifluoromethyl-pentanal 、 6-Fluoro-2-methylquinolin-5-amine 、 氰基硼氢化钠 生成 6-fluro-5-[4-(5-fluoro-2,3-dihydrobenzofuran-7-yl)-2-hydroxy-4-methyl-2-trifluoromethyl-pentylamino]-2-methylquinoline
  参考文献：
  名称：

  5-substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents

  摘要：

  通式为(IIa)或(IIb)的化合物及其作为药物代理的用途。

  公开号：

  US07417056B2

文献信息

• 5-Substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents
  申请人：Jaroch Stefan

  公开号：US20060116396A1

  公开（公告）日：2006-06-01

  Compounds of general formula (IIa) or (IIb) and their use as pharmaceutical agents.

  通式为（IIa）或（IIb）的化合物及其作为药物的用途。
• Cyclodextrin-based polymers for therapeutics delivery
  申请人：Davis E. Mark

  公开号：US20060210527A1

  公开（公告）日：2006-09-21

  The present invention relates to novel compositions of therapeutic polymeric compounds designed as carriers for small molecule therapeutics delivery and pharmaceutical compositions thereof. In some embodiments, the small molecule therapeutic is attached to the polymer by a photocleavable linker. The polymeric compounds may also employ targeting agents. By selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. On reaching a targeted site in the body of a patient, the linker can then be cleaved by the shining of ultraviolet, visible, or infrared wavelength light onto the site. The methods provide reduced toxicity and local delivery of therapeutics. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting a pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.

  本发明涉及新型治疗聚合物化合物的组成，设计为小分子治疗剂传递的载体及其制药组合物。在某些实施例中，小分子治疗剂通过光解链连接到聚合物上。聚合物化合物也可以使用靶向剂。通过从各种连接基团和靶向配体中进行选择，聚合物提供了控制治疗剂传递的方法。当到达患者体内的靶向部位时，可以通过在该部位照射紫外线、可见光或红外线波长光来裂解连接剂。该方法提供了治疗剂的降低毒性和局部传递。本发明还涉及使用所述治疗组合物治疗受试者的方法。本发明还涉及用于进行制药业务的方法，包括制造、许可或分发包含或涉及所述聚合物化合物的试剂盒。
• CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY
  申请人：Cheng Jianjun

  公开号：US20120065368A1

  公开（公告）日：2012-03-15

  The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.

  本发明涉及一种新型治疗环糊精含聚合物化合物组成，设计为小分子治疗药物的载体及其制药组合物。这些含环糊精聚合物可以提高药物的稳定性和溶解性，并在体内使用时降低小分子治疗药物的毒性。此外，通过从各种连接基团和靶向配体中进行选择，这些聚合物提供了控制治疗剂的递送方法。本发明还涉及使用上述治疗组合物治疗受试者的方法。本发明还涉及进行制药业务的方法，包括制造、许可或分发包含或与上述聚合物化合物相关的试剂盒。
• CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTIC AGENTS COVALENTLY BOUND THERETO
  申请人：Cheng Jianjun

  公开号：US20150165055A1

  公开（公告）日：2015-06-18

  The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.

  本发明涉及一种新型治疗环糊精含聚合物组成物，作为小分子治疗药物的载体，以及其制药组合物。这些含环糊精聚合物可以提高药物稳定性和溶解度，并在体内使用时减少小分子治疗药物的毒性。此外，通过从各种连接基团和靶向配体中选择聚合物，可以实现对治疗剂的控制释放方法。本发明还涉及使用所述治疗组合物治疗受试者的方法。本发明还涉及制药业务的方法，包括制造、许可或分销包含或涉及所述聚合物化合物的试剂盒。
• COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, OR AMELIORATING INFLAMMATORY PAIN
  申请人：Ward Keith W.

  公开号：US20120316199A1

  公开（公告）日：2012-12-13

  A composition for treating, controlling, reducing, or ameliorating inflammatory pain comprises a dissociated glucocorticoid receptor agonist (“DIGRA”), a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable ester thereof. The composition can comprise an additional anti-inflammatory agent and can be formulated for topical application, injection, or implantation. It may be used in a method of managing post-surgical ocular pain such that it has lower risk of eliciting adverse side effects seen with other therapeutic agents.

  用于治疗、控制、减轻或改善炎症性疼痛的组合物包括解离型糖皮质激素受体激动剂（“DIGRA”）、其前药、其药学上可接受的盐或其药学上可接受的酯。该组合物可以包含额外的抗炎药物，并可制成局部应用、注射或植入剂。它可以用于管理术后眼部疼痛的方法，从而降低与其他治疗剂产生的不良副作用风险。